Melanoma Clinical Trial
Biological Therapy in Treating Patients With Metastatic Melanoma
Summary
RATIONALE: Biological therapies such as cellular adoptive immunotherapy use different ways to stimulate the immune system and stop cancer cells from growing. Treating a person's white blood cells in the laboratory and then reinfusing them may cause a stronger immune response and kill more tumor cells.
PURPOSE: Phase I trial to study the effectiveness of biological therapy in treating patients who have metastatic melanoma.
Full Description
OBJECTIVES:
Primary
Determine the safety and toxicity of cellular adoptive immunotherapy comprising autologous CD8+ cytotoxic T-lymphocyte clones targeting cancer-testis antigens in patients with metastatic melanoma.
Determine the duration of in vivo persistence of this therapy in these patients.
Secondary
Evaluate the antitumor effects of this therapy in these patients.
OUTLINE: Patients undergo leukapheresis to obtain peripheral blood mononuclear cells and then CD8+ cytotoxic T-lymphocyte (CTL) clones are generated ex vivo. Patients receive cellular adoptive immunotherapy comprising autologous CD8+ CTL clones targeting cancer testis antigens IV over 30 minutes on day 1. Patients also receive interleukin-2 subcutaneously every 12 hours on days 1-14 of courses 2-4. Treatment repeats every 3 weeks for 4 courses in the absence of disease progression or unacceptable toxicity. Patients who demonstrate a clinical response after completion of the fourth course are eligible to receive additional T-cell infusions.
Patients are followed for 9 months.
PROJECTED ACCRUAL: A total of 20 patients will be accrued for this study within 3 years.
Eligibility Criteria
DISEASE CHARACTERISTICS:
Histologically confirmed metastatic melanoma
Stage IV disease
HLA-A1, -A2, and -A3 positive
MAGE-1 or -3 positive by histology
Bidimensionally measurable disease by palpation on clinical examination, x-ray, or CT scan
No CNS metastases
PATIENT CHARACTERISTICS:
Age
18 to 75
Performance status
Karnofsky 80-100%
Life expectancy
More than 6 months
Hematopoietic
Not specified
Hepatic
Bilirubin ≤ 1.6 mg/dL
SGOT ≤ 3 times upper limit of normal
PT ≤ 1.5 times control
Renal
Creatinine ≤ 2.0 mg/dL
Calcium ≤ 12 mg/dL
Cardiovascular
No congestive heart failure
No clinically significant hypotension
No symptoms of coronary artery disease
No cardiac arrhythmias on electrocardiogram requiring drug therapy
Patients with prior cardiovascular disease or the presence of any of the above abnormalities undergo a cardiac evaluation, which may include a stress test and/or echocardiogram
Pulmonary
No clinically significant pulmonary dysfunction by medical history or physical examination
FEV_1 ≥ 60% of normal
DLCO ≥ 55% (corrected for hemoglobin)
Other
Not pregnant or nursing
Negative pregnancy test
Fertile patients must use effective contraception
No retinitis or choroiditis
No active infections or oral temperature greater than 38.2 degrees Celsius within the past 72 hours
No systemic infection requiring chronic maintenance or suppressive therapy
PRIOR CONCURRENT THERAPY:
Biologic therapy
No other concurrent immunotherapy (e.g., other interleukins, interferons, melanoma vaccines, intravenous immunoglobulin, or expanded polyclonal tumor-infiltrating lymphocytes or lymphokine-activated killer cell therapy)
Chemotherapy
At least 3 weeks since prior standard or experimental chemotherapy
1-2 courses of prior cytoreductive chemotherapy for bulky disease allowed
Endocrine therapy
No concurrent systemic steroids (except for toxicity management)
Radiotherapy
At least 3 weeks since prior radiotherapy
Surgery
Not specified
Other
At least 3 weeks since prior immunosuppressive therapy
No concurrent pentoxifylline
No other concurrent investigational agents
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
Seattle Washington, 98109, United States
How clear is this clinincal trial information?
Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.